Alkem Laboratories’ Contract Research Organisation (CRO) facility in Taloja, Maharashtra, underwent an unannounced inspection by the US Food and Drug Administration (FDA) on 8th May 2026. The inspection concluded without the issuance of a form 483, indicating that no significant compliance issues were identified at the facility.
The inspection, which took place on the same day as the announcement, reflects the facility’s adherence to regulatory standards set by the US FDA. A form 483 is typically issued when investigators observe any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
This development is significant for Alkem Laboratories as it underscores the company’s commitment to maintaining high standards of compliance and operational excellence in its CRO operations. The absence of a form 483 suggests that the Taloja facility is operating in accordance with the stringent requirements of the US FDA, which is crucial for the company’s ongoing business activities and reputation in the pharmaceutical industry.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).